Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Alshaygy on Resection Margin for Dermatofibrosarcoma Protuberans

November 18th 2019

Ibrahim S. Alshaygy, MD, MSC, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans.

Early Data Support Neoadjuvant Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 9th 2019

Joshua M. Lawrenz, MD, discusses the use of hypofractionated radiotherapy versus conventional radiotherapy in soft tissue sarcoma.

First-Ever Global Prospective Trial in Orthopedic Oncology Completes Accrual

November 5th 2019

Michelle Ghert, MD, FRCSC, discusses the PARITY and SAFETY trials and the future of research in orthopedic oncology.

Dr. Lawrenz on Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 5th 2019

Joshua M. Lawrenz, MD, discusses a study looking at hypofractionated radiotherapy in soft tissue sarcoma.

Ongoing Research Explores Novel Approaches in Soft Tissue Sarcoma

November 2nd 2019

Albert J. Aboulafia, MD, discusses advances in tenosynovial giant cell tumor and the early research and challenges in soft tissue sarcoma treatment.

Dr. Eward on FDA Approval of Pexidartinib in TGCT

October 30th 2019

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Larger Surgical Margins Not Needed for Dermatofibrosarcoma Protuberans

October 29th 2019

Ibrahim S. Alshaygy, MD, MSC, discusses surgical developments in dermatofibrosarcoma protuberans and tenosynovial giant cell tumor.

Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

October 25th 2019

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Intriguing Research Brings Hope to Orthopedic Oncology

October 22nd 2019

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Neoadjuvant Immunotherapy Plus Radiation Shows Promise in Soft Tissue Sarcoma

October 22nd 2019

Vincent Y. Ng, MD, discusses what implications the NEXIS study could have in soft tissue sarcoma treatment and the next steps going forward.

Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

October 21st 2019

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Dr. Nasri on Risk Stratification in Osteosarcoma

October 16th 2019

Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.

Open-Minded Research for Therapeutic Options Needed in TGCT

October 10th 2019

William Eward, MD, DVM, discusses the use of pexidartinib and other options to treat patients with tenosynovial giant cell tumor, as well as future recommendations for the field, such as using comparative oncology when researching drugs.

Dr. Randall on Using Pexidartinib to Treat Tenosynovial Giant Cell Tumor

October 9th 2019

R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.

NCCN Grants Category 1 Recommendation to Pexidartinib for TGCT

September 27th 2019

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma to include a category 1 recommendation for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.

FDA Grants Nirogacestat Breakthrough Designation for Desmoid Tumors

September 4th 2019

The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in Sarcomas

September 3rd 2019

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.

Dr. Hurwitz on Patient Cohorts in the PIVOT-02 Trial

August 30th 2019

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor

August 2nd 2019

The FDA has approved pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor that is associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

FDA Grants Priority Review to Tazemetostat for Epithelioid Sarcoma

July 25th 2019

The FDA has granted a priority review to tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.